Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Modine Manufacturing | Pfizer | |
|---|---|---|
| Moat rating | none Modine's FY2026 Form 10-K (fiscal year ended 31 March 2026, filed 2026-05-27 as EDGAR accession 0001104659-26-066795; read from the copy on Modine's investor-relations site) describes competitive markets and no structural protection. It says "Most of our products are sold in competitive markets", that "pricing pressures from our customers and pricing actions of our competitors" may "require us to adjust the prices of products to stay competitive", that it experiences "competition from companies in other parts of the world that enjoy economic advantages, such as lower labor costs", and that if it cannot differentiate with technology "we may experience price erosion, lower sales, and lower profit margins." Stored fundamentals from Modine's 10-Ks show gross profit of $365.5 million on $2,212.7 million of revenue in fiscal 2019 and $389.4 million on $2,297.9 million in fiscal 2023; the FY2026 10-K reports gross margin of 24.9 percent for fiscal 2025 and 23.0 percent for fiscal 2026, and the Q1 fiscal 2027 release (2026-07-29) reports 20.8 percent. Customers are concentrated: the ten largest were 49 percent of fiscal 2026 net sales and "one global technology customer" about 11 percent. The strongest counter-evidence is in data centres, where on the Q4 fiscal 2026 call (https://s205.q4cdn.com/270741342/files/doc_financials/2026/q4/Modine_Transcript-Q4-FY26.pdf) the CEO announced an agreement under which "we will guarantee capacity to supply more than 4 billion of data center cooling products during calendar years 2027 through 2029"; but that is a capacity commitment to one existing customer, and the CFO added "Short of an LTA, we don't have multiyear POs. And what this one did is it gave us a really high confidence in a big portion of our two-, three-year outlook." Fast growth in a capacity-short market, without a protected position or a durable margin premium, is not shown to be a moat, so the band is none. | eroding The FY2025 10-K publishes the expiry schedule of its own protection. The Patents table dates the basic U.S. product patent on Eliquis ($7,961 million of 2025 revenue) to 2027, the Prevnar family's Prevnar 13 ($6,494 million for the family) to 2026, the Vyndaqel family ($6,380 million) to 2026 with a 2028 extension only pending, Ibrance ($4,122 million) to 2027, Xtandi ($2,194 million) to 2027 and Xeljanz ($1,087 million) to 2026 - against Total revenues of $62,579 million. The filing then states it anticipates 'a significant reduction of revenue from patent-based or regulatory exclusivity expiries in 2026 through 2030 as several of our in-line products experience these expirations, with the rate of the reduction of revenues from patent-based or regulatory exclusivity expiries expected to significantly accelerate over the next few years', and puts the 2026 instalment at $1.5 billion. A protection whose end dates the issuer tabulates product by product, and whose revenue effect it forecasts as accelerating, is being consumed on a clock it has already disclosed. |
| Moat type | none No moat source is demonstrated in the filings. The 10-K says "our business as a whole is not materially dependent upon any particular patent or license, or any particular group of patents or licenses", although Item 1A says intellectual property "plays an important role in maintaining our competitive position in a number of the markets we serve." Switching costs are the closest candidate: the 10-K says customers ask Modine, "as well as their other primary suppliers", for R&D, design and validation support, and on the Q1 fiscal 2027 call (https://s205.q4cdn.com/270741342/files/doc_financials/2027/q1/Modine_-Transcript-Q1-FY27.pdf) the CEO described a product designed with a specific hyperscaler "in probably the third iteration of the design cycle". But the same 10-K says "Generally, we supply products to our customers on the basis of individual purchase orders received from them", that long-term sales agreements are "typically three to five years in duration", and that its 80/20 pricing strategy "may result in a lower overall win rate for new business", which describes contestable rather than locked-in business. Scale is not claimed as an advantage either: the company competes with "many manufacturers of heat transfer and HVAC&R solutions, some of which are divisions of larger companies". The type is none. | intangibles ip The filing locates the protection in the patent estate, not anywhere else. The Patents and Other Intellectual Property Rights section tabulates 'the patent rights we consider most significant in relation to our business as a whole, together with the year in which the basic product patent expires', and states that once protection is lost 'we typically lose market exclusivity on these products, and generic and biosimilar pharmaceutical manufacturers generally produce identical or highly similar products and sell them for a lower price.' The Competition section names patents as the thing rivals attack: 'several of our competitors operate without large R&D expenses and make a regular practice of challenging our product patents before their expiration', and 'Generic pharmaceutical manufacturers pose one of the biggest competitive challenges to our branded small molecule products because they can market a competing version of our product after the expiration or loss of our patent protection.' No network, switching cost or cost-curve advantage is claimed anywhere in the section. |
| Leadership | fast follower The 10-K gives no share or rank and names no competitor; it says only "We compete with many manufacturers of heat transfer and HVAC&R solutions, some of which are divisions of larger companies." The independent view is Dell'Oro Group's 3Q 2025 data center physical infrastructure release (2025-12-10, https://www.delloro.com/news/data-center-physical-infrastructure-market-expands-18-percent-y-y-in-3q-2025/), which grouped Modine with rising entrants: "Emerging competitors continued to gain momentum, with Aaon scaling its data center thermal business by an order of magnitude within a few quarters, supported by a very healthy backlog as hyperscalers broaden their supplier base. Modine also strengthened its position, securing notable hyperscale wins that reinforce its rising relevance in large AI campus deployments." On the Q4 fiscal 2026 call the CEO said "From a market demand standpoint, we're in a great competitive position", which is the company's own view. A supplier gaining ground with hyperscalers, described by a tracker as of rising relevance rather than as a leader, is a fast follower. | co leader The 2026 Pharma 50 (Drug Discovery & Development, published 31 March 2026, ranking pharmaceutical revenue only) places Pfizer third at $62.58 billion of FY2025 revenue inside a five-company band that runs from Johnson & Johnson's Innovative Medicine at $60.40 billion to Eli Lilly's $65.18 billion, with Merck & Co. at $65.01 billion and AbbVie at $61.16 billion in between - scale-equal to its nearest peers rather than ahead of them. The same piece attributes the top slot to Lilly's tirzepatide franchise, which it puts at $36.5 billion combined and says passed Keytruda as the world's best-selling drug; Pfizer's 10-K names no comparable single franchise, discloses no market-share position for any product, and concedes in Item 1A that 'some of our competitors may have competitive, technical or other advantages over us' and that it faces 'an increasing number of potential competitors worldwide, including from China, that have expanded R&D capabilities.' |
| Pricing power | weak The filing describes price as something Modine defends rather than sets. Item 1A says "Our sales levels and margins could be adversely affected by pricing pressures from our customers and pricing actions of our competitors", and that its 80/20 pricing strategy, with "clear, strategic profit margin targets for new sales", "may result in a lower overall win rate for new business." Cost recovery is mechanical and lagged: contract adjustments are "limited to the underlying cost of the material", "typically do not include related metals premiums or fabrication costs", and can take "a three-month to one-year lag"; on the Q4 fiscal 2026 call the CFO said "we'll recover tariffs through surcharges and mitigate increasing metals prices with pricing mechanisms in our customer contracts." The fiscal 2025 margin gain in Climate Solutions came "primarily due to favorable sales mix and the favorable impact of commercial pricing settlements"; company gross margin then fell 190 basis points to 23.0 percent in fiscal 2026 and was 20.8 percent in Q1 fiscal 2027 (https://s205.q4cdn.com/270741342/files/doc_financials/2027/q1/Modine-Reports-First-Quarter-Fiscal-2027-Results.pdf). On the Q1 fiscal 2027 call the CEO said the company is "taking decisive pricing actions to offset inflationary cost increases, including materials and tariffs", which is cost recovery, not evidence of a price premium. | weak Price is the lever the filing shows moving against it. CMS selected Eliquis - which the 10-K says 'accounted for 13% of Total revenues in 2025' - for the Medicare Drug Price Negotiation Program, and 'its government-set Maximum Fair Price became effective January 1, 2026', with Ibrance and Xtandi following in 2027 and Xeljanz in 2028. In September 2025 Pfizer 'voluntarily agreed' with the U.S. administration to make certain U.S. prices 'more comparable to those in other developed countries' and to sell through the TrumpRx.gov platform 'at significant discounts to current retail prices'. Gross-to-net product revenue deductions rose to $36,374 million in 2025 from $30,048 million in 2023 while Total revenues fell to $62,579 million, and the IRA Medicare Part D Redesign alone 'negatively impacted our 2025 revenues by approximately $1 billion'. Lower U.S. net price is named as a drag on Vyndaqel, Ibrance, Xeljanz, Nurtec ODT and Lorbrena; every 2025 growth line the filing explains is attributed to demand, patient share or launch uptake, none to price. Cost of sales at 25.7% of revenues shows the manufactured margin is intact - what is not intact is the ability to set the price. |
| Summary | Modine makes thermal management products in two groups, per its FY2026 10-K: Climate Solutions (data centre cooling, heat transfer coils and coatings, refrigeration and power-generation coolers, and HVAC heating and indoor-air-quality products) and Performance Technologies (heat exchangers and cooling modules for vehicles, off-highway equipment and generator sets). Data centre products rose to 35 percent of fiscal 2026 net sales from 25 percent; they include chillers, dry coolers, precision air handling units, CRAC and CRAH units, fan walls, rear-door heat exchangers, coolant distribution units and immersion solutions, sold to hyperscale, colocation, NeoCloud and edge customers. Fiscal 2026 net sales were $3.2 billion, up 23 percent, and on the Q4 fiscal 2026 call the CEO said data centre sales "increased 73% to 1.1 billion" and announced a capacity agreement covering "more than 4 billion of data center cooling products during calendar years 2027 through 2029" with an existing customer. Modine plans to spin off Performance Technologies and combine it with Gentherm, which it expects to close by the end of calendar 2026, leaving a data centre and commercial HVAC company. An independent tracker, Dell'Oro Group (2025-12-10), described Modine among "emerging competitors" that "strengthened its position, securing notable hyperscale wins". The limits are in the 10-K and recent results: most products are sold "in competitive markets" under customer pricing pressure, the ten largest customers were 49 percent of sales, no single patent is material, and gross margin was 23.0 percent in fiscal 2026 and 20.8 percent in Q1 fiscal 2027, when the Data Centers segment's gross margin fell 960 basis points to 20.2 percent on capacity expansion costs and supply shortages. Strong demand and customer co-design are real, but the filings show no protected position or margin premium, so Modine is rated as having no moat. | Two clocks run in opposite directions inside the same company. The revenue base is near-dated: Eliquis, the Prevnar family, the Vyndaqel family, Ibrance, Xtandi and Xeljanz all carry U.S. basic product patents expiring 2026 or 2027 in the 10-K's own table, and the filing warns the resulting revenue loss will 'significantly accelerate over the next few years'. The replacement book is later-dated - Padcev and Lorbrena to 2033, Nurtec ODT and Litfulo to 2034, Prevnar 20 to 2035, Abrysvo, Cibinqo and Elrexfio to 2036, Comirnaty and Paxlovid to 2041 - but in 2025 it was still much smaller, and the two products with the longest patent runway are the two the filing says are shrinking fastest (Comirnaty down 20% and Paxlovid down 59% operationally). The 10-K's answer is purchased pipeline rather than defended position: it cites the Seagen and Metsera acquisitions as 'significant investments in obesity and oncology, respectively, which are extremely competitive therapeutic areas', while R&D expense itself fell 4% to $10,437 million. Excluding Comirnaty and Paxlovid the remaining business grew 6% operationally in 2025, which is the honest measure of what is being rebuilt underneath the expiries. A third pressure sits on top of the patent clock and is independent of it: government price-setting now reaches the largest product in the book. |
| Chain position | Modine supplies facility-level cooling for AI data centres, chiefly chillers and air handling units with a smaller CDU line; on the Q1 fiscal 2027 call the CEO said order growth came from "the three largest customers that we have that are hyperscaler and Neocloud", and the 10-K names one global technology customer at about 11 percent of fiscal 2026 sales. | Demand side of the AI chain, not a supplier into it. The 10-K lists 'Scale AI across our business' as one of four 2026 key priorities and describes 'expanding automation, data-driven decision making, and enterprise AI solutions', crediting 'enhanced digital enablement, including automation and AI' for part of the savings in its cost-realignment and R&D-simplification programs. It describes no AI model, tool or platform that Pfizer sells. |
| Products (share / barrier) |
|
|
| Long-horizon vote | -0.06 at weight 0.20 · swarm neutral Editorial prior, not backtested. | -0.17 at weight 0.20 · swarm bearish Editorial prior, not backtested. |